Three-year follow-up from MeiraGTx’s Phase 1 AQUAx study showed sustained, clinically meaningful improvements in patient-reported xerostomia symptoms and persistent gains in unstimulated whole saliva flow after a single administration of AAV-hAQP1, with a safety profile deemed acceptable across tested doses. Durability signals were observed in both unilateral and bilateral dosing cohorts, with no new safety findings through 36 months.
The update completes the 36-month dataset from an open-label, dose-escalation trial in patients with grade 2/3 late radiation-induced xerostomia who were cancer-free for at least five years (two years for HPV-positive). AAV-hAQP1 was delivered via Stensen’s duct into one or both parotid glands. While safety was the primary endpoint, the program tracks efficacy through a validated patient-reported outcome (Xerostomia Questionnaire) alongside objective saliva flow measures. Participants will continue to five years of follow-up.
Strategically, the readout positions MeiraGTx to advance a gene therapy aimed squarely at survivorship morbidity rather than rare monogenic disease or life-threatening conditions. A one-time, in-office ductal infusion that confers multi-year symptom relief would be operationally attractive if replicated in controlled studies: no chronic dosing, limited infusion infrastructure, and a local delivery paradigm designed to minimize systemic exposure. It also moves the gene therapy conversation into a quality-of-life domain where regulators and payers will demand clear, durable, and functionally meaningful benefit backed by robust PRO methodology and objective corroboration. The absence of numerical data in this update leaves unanswered questions about effect size distributions across cohorts and consistency thresholds regulators will expect in later-stage trials.
For sites, this program requires capabilities more common to ENT/oral surgery and salivary gland procedures than to traditional infusion centers. Centers will need training for duct cannulation, standardized saliva flow assessments, and validated PRO capture, along with gene therapy handling, storage, and long-term follow-up workflows. The eligibility criteria funnel recruitment to head-and-neck oncology survivorship clinics with established radiation histories, which can streamline identification but will require cross-specialty coordination to confirm remission timelines and manage comorbidities typical of this population. CROs and sponsors should anticipate that a randomized, controlled design with sham or procedure control will be necessary to address placebo and procedural effects inherent to interventional local therapies, alongside centralized reading of saliva metrics and rigorous immunogenicity and shedding surveillance.
Regulatory focus is likely to converge on durability, retreatment feasibility in the context of AAV immunity, vector biodistribution, and CMC scalability as the program transitions to multisite trials. Local administration may mitigate some systemic AAV concerns seen elsewhere, but comparability as manufacturing scales and as vector lots evolve will be scrutinized. Payers will look for linkage between PRO improvements, functional outcomes such as dysphagia relief or sleep quality, and healthcare utilization reductions, given that xerostomia is often managed with symptomatic measures that carry modest cost but limited efficacy.
Next steps should include a randomized, adequately powered study with a prespecified PRO primary and objective co-primary or key secondary endpoint, clear responder definitions, and bilateral versus unilateral dosing algorithms that can be operationalized at scale. Watch for details on patient stratification by baseline gland function, durability beyond three years as five-year data mature, and any movement toward expedited pathways such as RMAT. The key risks remain the open-label nature of the Phase 1 dataset, the need for procedural standardization across community and academic sites, and the commercial test of whether a gene therapy addressing quality-of-life morbidity can secure broad coverage and predictable site economics.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
